News

Theratechnologies Inc. announced that it has filed a supplemental new drug application (sNDA) with the Food and Drug Administration (FDA) for a single-vial formulation of EGRIFTA.…
Read More...

Treating advanced breast cancer with three drugs instead of one could boost the effectiveness of treatment and stop tumours developing resistance, a new study reports. Researchers…
Read More...

Recipharm has announced the launch of its standalone serialisation service ahead of the introduction of the EU Falsified Medicines Directive (FMD). The new service is designed to…
Read More...

A. Menarini Asia-Pacific Holdings Pte Ltd, a member of the Italian largest biopharmaceutical company Menarini Group, and Orion Corporation have signed a multi-year licensing agreement…
Read More...

Merz North America announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for XEOMIN (incobotulinumtoxinA) for the…
Read More...

Evotec AG announced that the strategic transaction signed on 15 June 2018, to integrate Sanofi’s infectious disease unit including licensing-in the majority of Sanofi’s infectious…
Read More...

Sanofi is launching a Global R&D Operations Hub with a specialized focus on digitalization and big data analysis in Chengdu, Sichuan province, China. The new R&D operations hub…
Read More...

AstraZeneca and Merck & Co., Inc., Kenilworth, N.J., US (Merck: known as MSD outside the US and Canada) announced that Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) has…
Read More...

Abcam announced the commercial launch of the new anti-PD-L1 antibody clone MKP1A07310 (clone 73-10) developed in collaboration with Merck KGaA, Darmstadt, Germany. Developed by Abcam…
Read More...

Adamis Pharmaceuticals Corporation announced that it has entered into an exclusive distribution and commercialization agreement with Sandoz, a division of the Novartis Group, to…
Read More...

Alkermes plc announced that the U.S. Food and Drug Administration (FDA) has approved ARISTADA INITIO (aripiprazole lauroxil) for the initiation of ARISTADA (aripiprazole lauroxil), a…
Read More...

Agilent Technologies announced that it has entered into a definitive agreement to acquire privately-held ProZyme, Inc., a leading provider of glycan analysis reagents, kits and…
Read More...

OWC Pharmaceutical Research Corp. announced a successful completion of the first part of its Phase I, placebo controlled, maximal dose study to determine the safety and tolerability of…
Read More...

Akebia Therapeutics and Keryx Biopharmaceuticals announced that the companies signed, and the boards of directors of both companies have unanimously approved, a definitive merger…
Read More...

The Broad Institute of MIT and Harvard and Bayer are launching the Precision Cardiology Laboratory (PCL), a new endeavor that will pursue scientific insights aimed at developing new…
Read More...

Kite, a Gilead Company announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion on the company’s…
Read More...

Pfizer Inc. announced that the European Commission (EC) has approved XELJANZ (tofacitinib citrate) 5 mg twice daily (BID) in combination with methotrexate (MTX) for the treatment of…
Read More...

Sanofi and Advent International have finished negotiations for the acquisition of Zentiva, Sanofi's European generics business, by Advent and the companies have signed a Share Purchase…
Read More...

Purdue Pharma announced successful completion of a first-in-human Phase 1 dose escalation study of tinostamustine in patients with relapsed or refractory hematological malignancies for…
Read More...

RedHill Biopharma Ltd. announced that it has entered into a co-promotion agreement with Napo Pharmaceuticals, Inc. (Napo), a human health company developing and commercializing novel…
Read More...